Vétoquinol S.A., a veterinary pharmaceutical laboratory, designs, develops, and sells veterinary drugs and non-medicinal products serving both the companion animals and livestock, and bred for human food markets in Europe, the Americas, and the Asia Pacific region. It offers pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction related products for dogs, cats, cattle, and pigs. The company offers its prdoucts under Tolfedine CS, Tolfine, Cimalgex, Flexadin, Caniviton, Diurizone, Marbocyl, Forcyl, Ceftiocyl, Clavaseptin, Clindaseptin, Cefaseptin, Kefloril, Aurizon, Oridermyl, Longamox, Pen-Histra-Strep, Doxicor, Amoxinsol, Aluspray, Linspec, Permacyl, UpCard, Prilium, Ipakitine/Epakitine, Azodyl, Rubenal, Flevox, Dolpac, Zylkene, and Zentonil brands. The company was founded in 1933 and is headquartered in Lure, France. Vétoquinol S.A. is a subsidiary of Soparfin SCA.
Size (employees)
2,036 (est)
Vetoquinol was founded in 1933

Vetoquinol Metrics

Vetoquinol Summary

Market capitalization

€593 M

Closing share price

Vetoquinol's current market capitalization is €593 M.

Vetoquinol Market Value History

Vetoquinol Online Presence

Vetoquinol Company Life